Abstract Pyridoxine-dependent epilepsy is a disease inherited as an autosomal recessive trait, characterized by rapid response to pharmacological dosages of pyridoxine. The defect has been suggested to reside in glutamate decarboxylase (GAD), since a mutant GAD with an abnormally high K m for a cofactor, pyridoxal phosphate, could not synthesize an adequate amount of γ-amino butyric acid [Scriver and Whelan (1969) Ann NY Acad Sci 166: 83]. To test this hypothesis, we studied two affected families by screening for mutations in the GAD mRNA and by analyzing a polymorphic marker in the GAD gene. Since two forms of GAD, GAD65 and GAD67, have been identified in human brain, we analyzed both forms. To overcome the limited accessibility of brain tissues, we utilized the minute amounts of GAD mRNAs ectopically transcribed in lymphoblasts. The ectopic GAD transcripts were amplified by reversetranscription-mediated, nested polymerase chain reaction for mutation analysis. Two and three base substitutions were found in GAD65 and GAD67 cDNAs, respectively. All of them were, however, polymorphisms that were also found in control subjects. We then examined a (CA) repeat polymorphism in the GAD65 gene and found that different maternal alleles were transmitted to two affected sibs in one family. Thus, an etiological mechanism other than a K m mutant GAD is responsible for pyridoxine-dependent epilepsy.
Introduction
Pyridoxine-dependent epilepsy was first reported as a specific form of neonatal epilepsy (Hunt et al. 1954) , and is characterized by generalized seizures that are refractory to the standard anticonvulsants, but respond to pharmacological doses of pyridoxine (Scriver and Gibson 1995) . The dependency is permanent. If daily oral supplementation with pyridoxine is interrupted, seizures recur within several days. This is an inherited disease with an autosomal recessive trait (MIM266100). The gene responsible for this genetic disease is unknown. Scriver and Whelan (1969) suggested an etiological hypothesis with respect to a mutant glutamate decarboxylase (GAD: EC4.1.1.15), a γ-amino butyric acid (GABA) synthesizing enzyme; a mutation in the GAD gene would create a mutant form of GAD with an abnormally high K m for its cofactor pyridoxal phosphate (PLP). This mutation has been widely cited as the most likely etiology for this disorder. To verify the hypothesis, the enzymatic activities of GAD were examined in kidney , frontal cortex (Lott et al. 1978) , and cultured skin fibroblasts (Gospe et al. 1994 ) from patients. The interpretations of these results were, however, still moot (Scriver and Gibson 1995) . These circumstances prompted us to undertake the molecular analysis of the GAD.
This study was designed to demonstrate the existence of a kinetic mutant of GAD by screening for mutations in the GAD mRNA of the patients. Since two forms of GAD, GAD65 and GAD67, are expressed in brain, we analyzed both isozymes (Bu et al. 1992; Bu and Tobin 1994) . To overcome the limited accessibility of brain tissue from the patients, we used illegitimate GAD mRNA in the lymphoblasts. Illegitimate mRNA corresponds to the very low levels of transcript of a specific gene in nonspecific cells (Sarkar and Sommer 1989; Takahashi et al. 1992) . The GAD65 and GAD67 cDNA fragments were amplified for direct sequence analyses. Another approach used in this study was allele transmission analysis with a polymorphic marker which we recently identified in the GAD65 gene (Kure et al. 1997) . These two molecular approaches enabled us to test the etiological hypothesis for pyridoxinedependent epilepsy.
Patients and methods
Patients. Two affected families (A and B) showed typical responses to pyridoxine treatment. Family A had two affected children, a brother and a sister. The case history of the brother was previously described (Iinuma et al. 1971) and the clinical symptoms of the brother and the sister were similar. In family B, a healthy sister and an affected boy were born to nonconsanguineous parents. The patient first had generalized convulsions at 9 hours of age. At 53 h after birth, the patient received an intravenous administration of 20 mg pyridoxine and the seizures disappeared within 3␣ min. To confirm the diagnosis of pyridoxine-dependent epilepsy, pyridoxine administration was discontinued when he was 6 months old. Generalized convulsions developed within 3 days. He was placed on oral pyridoxine therapy again and had neither convulsions nor developmental delay, but a mild weakness of muscle tone.
Direct sequence analysis of GAD65 and GAD67 cDNA fragments. Procedures for cDNA synthesis from lymphoblast cells were previously reported . The sequences of primers used in this study are shown in Table␣ 1. The entire coding regions of the GAD65 and GAD67 cDNA were amplified in the first round PCR with HGAD 2ϫ8 and HGAD 21ϫ23, respectively. Seven and twelve overlapping cDNA fragments were amplified in second-round PCR for GAD65 and GAD67, respectively. The primer sets for the GAD65 cDNA were HGAD 1 ϫ 13, 9 ϫ 13, 10 ϫ 13, 3 ϫ 14, 11 ϫ 14, 5 ϫ 15, and 12 ϫ 15, while those for the GAD67 cDNA were HGAD 24 ϫ 47, 54 ϫ 47, 43 ϫ 47, 55 ϫ 47, 44 ϫ 14, 56 ϫ 14, 45 ϫ 14, 57 ϫ 14, 5 ϫ 16, 58 ϫ 16, 46 ϫ 16, and 59 ϫ 16. The sequence of M13 reverse primer was added to the 5Ј ends of the forward primers, and the reverse primers were 5Ј-labelled with biotin (Table␣ 1). Single-strand templates were prepared with avidin-coated magnetic beads (Dynal, Oslo, Norway), and subjected to dideoxy sequencing analysis with a fluorescence-labelled M13 reverse primer and an A.L.F. DNA Sequencer (Pharmacia, Uppsala, Sweden).
Polymorphic marker analysis. Polymorphic patterns of a (CA)-repeat region in the GAD65 gene were identified as previously reported (Kure et al. 1997) . Fluorescencelabeled DNA fragments were used as the size standards (Applied Biosystems, Foster City, CA, USA).
Results
Amplification and sequence analysis of the GAD65 cDNA fragments
The GAD65 cDNA was amplified from the ectopic GAD mRNA in lymphoblasts by reverse-transcription-mediated, nested PCR. Seven overlapping GAD65 cDNA fragments contained the whole protein-coding region of GAD65 cDNA. No difference in size was observed among the amplified cDNA fragments from the patients and controls. Direct sequence analysis revealed two homozygous nucleotide substitutions in all patients examined, T790C and T1597A, both of which caused no amino acid change. Both T790C and T1597A substitutions were also observed in five control lymphoblast cells in a homozygous form.
Amplification and sequence analysis of GAD67 cDNA fragments Twelve overlapping GAD67 cDNA fragments were amplified. Direct sequence analysis of each GAD67 cDNA fragment revealed three base substitutions, C661T, G753A, and T1852C. The G753A and T1852C were found in a homozygous form in all three patients, while the C661T substitution was detected in a heterozygous form in all the patients. Both C661T and T1852C substitutions caused no amino acid substitution, while the G753A resulted in an amino acid replacement, of arginine by lysine, at amino acid position 68. All three substitutions were, however, also found in five Japanese control subjects.
Analysis of a polymorphic marker in the GAD65 gene
To elucidate a transmission profile of each GAD65 gene allele in the affected family A, we examined the patterns of CA repeat polymorphism in intron 15 of the GAD65 gene (Kure et al. 1997) . Observed alleles for the father, the mother, the affected brother, and the affected sister were (21 repeats, 27 repeats), (20, 25), (21, 25) , and (20, 21), respectively (Fig. 1) . Both of the affected sibs inherited the allele of 21 repeats from their father, whereas they inherited different maternal alleles. The brother inherited the allele of 25 repeats, whereas the sister inherited the allele of 20 repeats.
Discussion
We studied the entire protein-coding regions of both GAD65 and GAD67 mRNAs from patients with pyridexine B6 dependent epilepsy. If there were a mutant GAD65 or GAD67 with an abnormal K m for PLP, a mutant GAD mRNA with an altered protein-coding region would need to exist. Five nucleotide changes were found; two in GAD65 cDNA and three in GAD67 cDNA. Four of them caused no amino acid change, while one base change in the GAD67 mRNA, G753A, caused a basic amino acid substitution from arginine to lysine at amino acid position 68. Homozygotes of G753A were, however, found among the control subjects, suggesting that G753A was not a mutation responsible for pyridoxine-dependent epilepsy, but a polymorphism commonly observed in Japan. Four other silent base changes were also found in the control subjects. Thus far, there is no evidence that altered forms of GAD65 or GAD67 mRNA existed in the cells from patients with pyridoxine-dependent epilepsy.
Based on the allele transmission analysis, it seems unlikely that the GAD65 gene is responsible for pyridoxine dependency. The analysis of (CA)-repeat polymorphism in the GAD65 gene suggested that the two affected sibs of family A inherited the different maternal alleles of the GAD65 gene. If the GAD65 gene were responsible for pyridoxine-dependent epilepsy, this result would serve to contradict the clinical observation that pyridoxinedependent epilepsy is inherited as an autosomal recessive trait. We attempted to find a (CA) repeat region in the GAD67 gene by the same method but failed. Since two affected sibs in family A had the same pattern of three exonic polymorphisms found in the GAD67 gene, C661T, G753A, and T1852C, we could not exclude the GAD67 gene from the candidate pool of genes by polymorphic marker analysis alone.
Taken together, these results suggest that an etiological mechanism other than a K m mutant GAD may operate in pyridoxine-dependent epilepsy. 
